Tumors evade immune cytotoxicity by altering the surface topology of NK cells-Reference-Cited by-同舟云学术

Tumors evade immune cytotoxicity by altering the surface topology of NK cells

Published:2023-03-23 Issue:5 Volume:24 Page:802-813
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Zheng Xiaohu^ORCID,Hou Zhuanghao,Qian Yeben,Zhang Yongwei,Cui Quanwei,Wang Xuben,Shen Yiqing,Liu Zhenbang,Zhou Yonggang,Fu Binqing,Sun Rui^ORCID,Tian Zhigang^ORCID,Huang Guangming^ORCID,Wei Haiming^ORCID

Funder

CAMS Innovation Fund for Medical Sciences

National Natural Science Foundation of China

The Strategic Priority Research Program of the Chinese Academy of Sciences

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41590-023-01462-9.pdf

Reference57 articles.

1. Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539–573 (2016).

2. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

3. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

4. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. & Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212–1218 (2013).

5. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257–265 (2015).

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification;Cancer Medicine;2024-09

2. Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy;iScience;2024-09

3. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis;Immunity;2024-09

4. Rab5 Overcomes CAR T Cell Dysfunction Induced by Tumor-Mediated CAR Capture;2024-07-26

5. Decoupling individual host response and immune cell engager cytotoxic potency;2024-06-25